Biography: Dr. Shanta Dhar was born in West Bengal, India. She received her Ph. D. from the Indian Institute of Science, Bangalore, India. Her graduate work was in the area of bioinorganic chemistry with the overall goal to develop copper(II) complexes to effect photocleavage of double stranded DNA at longer wavelengths. She was awarded with Prof. S. Sunderajan Best thesis award, Indian Institute of Science (2005). In 2006, she came to this side of the globe and joined Johns Hopkins University as a postdoctoral fellow where she worked in the area of bioorganic chemistry with Prof. Marc M. Greenberg. During 2007-2010, Dr. Dhar was an Anna Fuller postdoctoral fellow in Prof. Stephen J. Lippard’s group at the Massachusetts Institute of Technology and her postdoctoral studies were focused on nanocarrier-mediated delivery of platinum-based drugs for their potential applications in cancer. Dr. Dhar joined the chemistry department at the University of Georgia as an assistant professor and the Regenerative Bioscience Center in August 2010. Dr. Dhar’s research interests focus on nanomedicine with particular interests in mitochondrial-dysfunction related diseases. She has published over 45 peer-reviewed articles and holds 10 patents on these topics. She has received Ralph E Powe junior faculty award (2011), Department of Defense Prostate Cancer Idea Development award (2012), Targeting Mitochondria 2012 Award for Scientific Contribution, American Heart Association Scientist Development award 2013, Georgia’s Top biomedical researcher 2014, Georgia’s 40 under 40, 2014, Thieme Chemistry Journal Award 2015, co-founder of PartiKula LLC, which recently received a Series A financing for $5 million, led by 2M Companies.►Read More
Research interests lie at the interface of chemistry and biology with particular emphasis on nanocarrier mediated delivery of metal-based drugs for their potential applications in various diseases and in the development of nano-vaccines. Focused on interdisciplinary approaches for drug development. Dhar lab strategically place research at the interface of biological chemistry and nanotechnology. Despite the progress made in using nanocarriers in cancer therapy to increase tissue accumulation of drug molecules to improve efficacy and to reduce unwanted side effects, successful sub-cellular targeting of drugs specifically to cell organelles has only recently gained broader recognition. Many drugs have target sites inside the cell, at specific cell organelles or even inside organelles such as mitochondria. Our research is directed to develop organelle targeting polymeric nanoparticle-metal complex constructs, and to study nanoparticle assisted targeted delivery and the anticancer properties. Dhar lab develops technologies that use a combination of conventional methods of cancer treatment and immunotherapy in a single nanoparticle platform to provide powerful low-cost tool to treat cancer in humans.
The ability to rationally design and construct a platform technology to develop new platinum(IV) [Pt(IV) ] prodrugs with functionalities for installation of targeting moieties, delivery systems, fluorescent reporters from a single precursor with the ability to release biologically active cisplatin by using well-defined chemistry is critical for discovering new platinum-based therapeutics.... ►Read More
- Inorganic Chemistry
- Biological Chemistry
- Materials Chemistry
- Publications by Shanta Dhar may be found at PubMed.